Non-Hodgkin Lymphoma News

Non-Hodgkin Lymphoma - Videos

STOP! You must read this information before you decide about your cancer treatment. Over 350 non-toxic natural and alternative treatments that have helped thousands of people beat their cancer. Over 2,000 testimonials! Success rates for surgery, chemo and radiation revealed! Free information on financial and other help available. Download this set of 4 e-Books and Reports NOW. It could save your life.

The set of e-books and reports at www.naturalcancertreatments.com gives you EVERYTHING you need to know about natural and alternative treatments for cancer.

Non-Hodgkin’s Lymphoma - News

Non-Hodgkin’s Lymphoma News

Non-Hodgkins Lymphoma - Google News
©2010 Google
Google News

Cancer in the family - Dubuque Telegraph Herald

Cancer in the family Dubuque Telegraph Herald The cancer returned in July 2008 as a Stage 4, large diffuse cell lymphoma non-Hodgkins lymphoma. Declared cancer-free in July 2009. ...

The Guardian

Spartacus Star Diagnosed With Cancer; Production Halted Seattle Post Intelligencer Whitfield, who plays Spartacus in the freshman series, was diagnosed with non-Hodgkin's lymphoma and is scheduled to begin treatment ... Spartacus star diagnosed with CancerExaminer.com 'Spartacus' delayed as star undergoes cancer treatmentUSA Today Spartacus' Andy Whitfield has non-Hodgkin Lymphoma but is determined to fight itThe Survivors Club Philadelphia Inquirer -TheCelebrityCafe.com -Cinema Blend all 333 news articles »

Cell Therapeutics Passes Factory Test Seattle Post Intelligencer Cell Therapeutics (NASDAQ: CTIC), the Seattle-based company developing pixantrone for non-Hodgkin's lymphoma, said today that the FDA has certified that a ... Cell Therapeutics gets FDA OK for production siteBusinessWeek Cell Therapeutics says FDA OKs manufacturing facilityReuters Good News for Cell TherapeuticsZacks.com BioMedReports (subscription) -Bizjournals.com all 54 news articles »

Morton fights off cancer Taunton Daily Gazette At the age of 3, Morton was diagnosed with Stage IV stomach cancer — classified as Non-Hodgkin's Burkitt's Lymphoma — a fast-moving, aggressive form of ... Morton's commitment felt in the Coyle-Cassidy communityTaunton Daily Gazette all 10 news articles »

India Talkies

Seaweed Extract Could Help Fight Lymphoma AHN | All Headline News Dead Sea, Jordan (AHN) - Scientists are looking to seaweed as a possible treatment for non-Hodgkin's lymphoma, they said at a conference in Jordan this week ... Seaweed May Help Treat LymphomaBusinessWeek Seaweed extract may help treat lymphomaTimes of India Seaweed extract possibly useful for non-Hodgkin lymphoma treatmentHealthJockey.com all 35 news articles »

USA Today

Crash ends Iditarod for cancer victim USA Today Moon is undergoing chemotherapy for non-Hodgkin's lymphoma, and felt he was off to a good start after four days in the 1049-mile race in Alaska. ... Park Ridge man's Iditarod dream ends with crashChicago Sun-Times Local man competes in Iditarod raceABC7Chicago.com all 5 news articles »

CBC.ca

Seaweed Extract Holds Promise as Lymphoma Treatment eMaxHealth Nearly 90 percent of lymphoma cases are non-Hodgkin's lymphoma, distinguished from the less common Hodgkin's lymphoma by the traits of the cancer cells. ... Seaweed extract gives hope for lymphoma treatmentTheMedGuru all 5 news articles »

Veteran Officer Diagnosed With Cancer WYFF Greenville ... be held Saturday in Anderson for Lt. Allen Hammond, a 21-year veteran of the Anderson Police Department who was diagnosed with non-Hodgkin's Lymphoma. ... and more »

Spotlight on senator's health | Philadelphia Inquirer | 02/21/2010 Philadelphia Inquirer Frank Lautenberg's announcement last week that he has non-Hodgkin's lymphoma returned the spotlight to the issue of succession if he cannot finish his term ... Lautenberg's Cancer Is Curable, Doctor SaysNew York Times Lautenberg has stomach cancer; will undergo chemotherapyThe Hill NJ Sen. Frank Lautenberg, 86, has stomach lymphomaUSA Today The Star-Ledger - NJ.com -Examiner.com all 829 news articles »

When after a child dies, something good remains Seacoastonline.com Their daughter, Molly, died last July after a five-month battle with anaplastic large cell lymphoma. She was 5 years old. The form of non-Hodgkin's lymphoma ...

The Leukemia & Lymphoma Society's LymphomaCAST
Podcast for those living with Hodgkin and non-Hodgkin lymphoma. Sponsored by The Leukemia & Lymphoma Society

NHL: Treatment Advances from ASH
December 17, 2009 NHL: Treatment Advances from the American Society of Hematology (ASH) Annual Meeting This program featured Jonathan W. Friedberg, MD, MMSc, Associate Professor of Medicine, Chief, Hematology/Oncology Division, Director, Hematological Malignancies Clinical Research, Wilmot Cancer Center, University of Rochester, Rochester, NY.
Treating Uncommon Lymphomas
October 14, 2009 Treating Uncommon Lymphomas: Dialogue With an Expert on T-Cell, MALT, and Waldenström Macroglobulinemia This program featured Richard R. Furman, MD, Assistant Professor, Center for Lymphoma and Myeloma, Division of Hematology and Oncology, Weill Medical College of Cornell University, New York, NY. This program was sponsored by The Leukemia & Lymphoma Society and was supported by grants from Allos Therapeutics, Inc. and Eisai Inc.
Emerging Therapies in NHL: Understanding Your Options
September 22, 2009 - Part 2 (Q&A) Emerging Therapies in NHL: Understanding Your Options This program featured Andrew D. Zelenetz, MD, PhD, Chief, Lymphoma Service, Division of Hematology/Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY. This program was sponsored by The Leukemia & Lymphoma Society and was supported by grants from Genentech BioOncology and biogen idec.
Emerging Therapies in NHL: Understanding Your Options
September 22, 2009 - Part 1 (Presentation) Emerging Therapies in NHL: Understanding Your Options This program featured Andrew D. Zelenetz, MD, PhD, Chief, Lymphoma Service, Division of Hematology/Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY. This program was sponsored by The Leukemia & Lymphoma Society and was supported by grants from Genentech BioOncology and biogen idec.
NHL: Understanding Diagnosis and Making Treatment Decisions
NHL: Understanding Diagnosis and Making Treatment Decisions June 24, 2009 - Part 2 (Q&A) This program featured Steven H. Bernstein, MD, Professor of Medicine, Co-Director, Lymphoma Biology Program, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY. This program was sponsored by The Leukemia & Lymphoma Society and was supported by an unrestricted educational grant from Genentech BioOncology and biogen idec. This program was in collaboration with Abrale, our partner organization. http://www.leukemia-lymphoma.org/all_page?item_id=492628
NHL: Understanding Diagnosis and Making Treatment Decisions
NHL: Understanding Diagnosis and Making Treatment Decisions June 24, 2009 - Part 1 (Presentation) This program featured Steven H. Bernstein, MD, Professor of Medicine, Co-Director, Lymphoma Biology Program, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY. This program was sponsored by The Leukemia & Lymphoma Society and was supported by an unrestricted educational grant from Genentech BioOncology and biogen idec. This program was in collaboration with Abrale, our partner organization. http://www.leukemia-lymphoma.org/all_page?item_id=492628
Update on Mantle Cell Lymphoma - Part 2
Update on Mantle Cell Lymphoma - Part 2 (Q&A) June 18, 2009 This program featured Owen A. O'Connor, MD, PhD, Associate Professor of Medicine, Director, Lymphoid Development and Malignancy Program, Chief, Lymphoma Service, Herbert Irving Comprehensive Cancer Center, New York-Presbyterian Hospital, Columbia University, New York, NY. This program was supported by Celgene and Millennium, The Takeda Oncology Company.
Update on Mantle Cell Lymphoma - Part 1
Update on Mantle Cell Lymphoma - Part 1 (Presentation) June 18, 2009 This program featured Owen A. O'Connor, MD, PhD, Associate Professor of Medicine, Director, Lymphoid Development and Malignancy Program, Chief, Lymphoma Service, Herbert Irving Comprehensive Cancer Center, New York-Presbyterian Hospital, Columbia University, New York, NY. This program was supported by Celgene and Millennium, The Takeda Oncology Company.
Emerging Therapies in Leukemia, Lymphoma & Myeloma
Emerging Therapies in Leukemia, Lymphoma & Myeloma June 16, 2009 This program featured Gail J. Roboz, MD, Associate Professor of Medicine, Director, Leukemia Program, Weill Medical College of Cornell University/New York-Presbyterian Hospital, New York, NY and John P. Leonard, MD, Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, Professor of Medicine, Weill Medical College of Cornell University/New York-Presbyterian Hospital, Clinical Director, New York - Cornell Center for Lymphoma and Myeloma, New York, NY and Robert Z. Orlowski, MD, PhD, Director, Myeloma Section, Associate Professor, Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX. This program was supported in part by Celgene.
News on NHL from the ASH Annual Meeting - Part 2
12/18/2008 - Part 2 (Q&A) News on NHL from the American Society of Hematology (ASH) Annual Meeting This program featured Bruce D. Cheson, MD, FACP, Professor of Medicine, Head of Hematology, Director, Hematology Research, Lombardi Cancer Center, Georgetown University Hospital, Washington, DC. This program was sponsored by The Leukemia & Lymphoma Society and was supported by an educational grant from Genentech BioOncology and Biogen Idec.
News on NHL from the ASH Annual Meeting - Part 1
12/18/2008 - Part 1 (Presentation) News on NHL from the American Society of Hematology (ASH) Annual Meeting This program featured Bruce D. Cheson, MD, FACP, Professor of Medicine, Head of Hematology, Director, Hematology Research, Lombardi Cancer Center, Georgetown University Hospital, Washington, DC. This program was sponsored by The Leukemia & Lymphoma Society and was supported by an educational grant from Genentech BioOncology and Biogen Idec.
Childhood Leukemia and Lymphoma: An Update
Childhood Leukemia and Lymphoma: An Update on Current and Emerging Therapies This program featured Sima Jeha, M.D., Director, Leukemia/Lymphoma Developmental Therapeutics, Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN. This program was sponsored by The Leukemia & Lymphoma Society and was supported by a grant from The Jeff Gordon Foundation.
NHL: Current Treatments and Emerging Therapies - Part 2
NHL: Current Treatments and Emerging Therapies September 8, 2008 - Part 2 (Q&A) This program featured Andrew D. Zelenetz, M.D., Ph.D., Chief, Lymphoma Service, Division of Hematology/Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY. This program was sponsored by The Leukemia & Lymphoma Society, and was supported by an unrestricted educational grant from Genentech BioOncology and Biogen Idec. For related information go to http://www.leukemia-lymphoma.org/all_page?item_id=492628
NHL: Current Treatments and Emerging Therapies - Part 1
NHL: Current Treatments and Emerging Therapies September 8, 2008 - Part 1 (Presentation) This program featured Andrew D. Zelenetz, M.D., Ph.D., Chief, Lymphoma Service, Division of Hematology/Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY. This program was sponsored by The Leukemia & Lymphoma Society, and was supported by an unrestricted educational grant from Genentech BioOncology and Biogen Idec. For related information go to http://www.leukemia-lymphoma.org/all_page?item_id=492628
Childhood Cancer Survivorship: The Family's Journey Forward
5/29/2008 This program featured Nancy F. Cincotta, M.S.W., L.C.S.W., A.C.S.W., B.C.D., psychosocial director, Camp Sunshine, Casco, ME. This program was sponsored by The Leukemia & Lymphoma Society.
Progress in NHL Treatment, Part 2
5/20/2008, Part 2 This program on non-Hodgkin lymphoma (NHL) featured John W. Sweetenham, M.D., professor of medicine, director of clinical research, Taussig Cancer Institute, Cleveland Clinic, Ohio. This program was sponsored by The Leukemia & Lymphoma Society. In collaboration with Abrale.
Progress in NHL Treatment, Part 1
5/20/2008, Part 1 This program on non-Hodgkin lymphoma (NHL) featured John W. Sweetenham, M.D., professor of medicine, director of clinical research, Taussig Cancer Institute, Cleveland Clinic, Ohio. This program was sponsored by The Leukemia & Lymphoma Society. In collaboration with Abrale.
Progress in Mantle Cell Lymphoma: Update from the Experts 2
4/30/2008 - Part 2 This program featured John P. Leonard, MD, The Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY and Brad S. Kahl, MD, Associate Professor of Medicine, Director, Lymphoma Service, University of Wisconsin School of Medicine and Public Health, Madison, WI. This program was sponsored by The Leukemia & Lymphoma Society and supported by Celgene and Millennium Pharmaceuticals.
Progress in Mantle Cell Lymphoma: Update from the Experts 1
4/30/2008 - Part 1 This program featured John P. Leonard, MD, The Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY and Brad S. Kahl, MD, Associate Professor of Medicine, Director, Lymphoma Service, University of Wisconsin School of Medicine and Public Health, Madison, WI. This program was sponsored by The Leukemia & Lymphoma Society and supported by Celgene and Millennium Pharmaceuticals.
Stem Cell Transplantation: Current Trends/Future Directions
2/21/2008 This program featured Armand Keating, MD, FRCP(C), Professor of Medicine, Director, Division of Hematology, Epstein Chair in Cell Therapy and Transplantation at the University of Toronto. Director, Cell Therapy Program at Princess Margaret Hospital/Ontario Cancer Institute in Toronto, Ontario, Canada. This program was sponsored by The Leukemia and Lymphoma Society. Click here for the direct link to the audio: http://lls.hipcast.com/deluge/c940160b-5502-04f4-cb52-949b96782aaf.mp3
Sexuality and Intimacy After Cancer
3/11/2008 This program featured Sage Bolte, MSW, LCSW, OSW-C, Oncology Counselor, Breast Cancer Program, Life with Cancer® Inova Cancer Services in Fairfax, Virginia. This program was supported by The Leukemia and Lymphoma Society. Alternate link to the audio: http://lls.hipcast.com/deluge/c8641f38-69d9-13d3-34c8-663ded82ead0.mp3
Practical Tips for Managing Your Finances and Insurance 2
11/28/07 This program featured Beth Darnley, chief program officer, Patient Advocate Foundation, Newport News, Virginia and Anita Welborn, LMSW, director, Information Resource Center (IRC), The Leukemia & Lymphoma Society, White Plains, NY. This program was sponsored by The Leukemia & Lymphoma Society. Alternate link to the audio: http://lls.hipcast.com/download/ad858520-9141-1dc0-83f9-d88f41c26ae8.mp3
Advocating For Your Child's Learning Needs
2/13/08 Advocating For Your Child's Learning Needs: Through Treatment and Beyond This program featured Daniel Armstrong, PhD, professor & associate chair, Department of Pediatrics, director, Mailman Center for Child Development, associate chief of staff, Holtz Children's Hospital at the University of Miami, Jackson Memorial Medical Center, director, University of Miami Sickle Cell Center, Miami, Florida. This program was part of our Focus on Childhood Cancers Educational Series and was sponsored by The Leukemia and Lymphoma Society. Alternate link to the audio: http://lls.hipcast.com/deluge/ceab5a99-d0bd-9b91-fe70-bcf68ea5001c.mp3
Practical Tips for Managing Your Finances and Insurance 1
11/28/07 Cancer Survivorship: Practical Tips for Managing Your Financial and Insurance Issues - Part 1 of 2 This program featured Beth Darnley, chief program officer, Patient Advocate Foundation, Newport News, Virginia and Anita Welborn, LMSW, director, Information Resource Center (IRC), The Leukemia & Lymphoma Society, White Plains, NY. This program was sponsored by The Leukemia & Lymphoma Society. Alternate link to the audio: http://lls.hipcast.com/download/2b62f7e8-7e73-ab61-88c1-70c8794e4aca.mp3
Spotlight on New Discoveries in NHL Part 2
12/12/2007 Update from the American Society of Hematoloty (ASH) Annual Meeting This program featured Wyndham Wilson, M.D., Ph.D, senior investigator, head, Lymphoma Therapeutics Section, National Cancer Institute, Bethesda, MD. Alternate link to the audio: http://lls.hipcast.com/deluge/c191974d-8461-640b-c8af-0f769e8a66da.mp3

Hematological Cancer News Articles Provided by Cancer Compass
CancerCompass is dedicated to provided you with the most up to date cancer information and news. Visit our website to find all our articles on Hematological Cancer News

New Cancer Treatment Gives Hope To Lymphoma And Leukemia Patients
Cancer researchers have high hopes for a new therapy for patients with certain types of lymphoma and leukemia. PCI-32765 is a new drug being assessed in a Phase I clinical trial at the Virginia G. Piper Cancer Center in collaboration with the Clinical Division of the Translational Genomics Research Institute (TGen).
Chemotherapy Or Pills? Difference Can Be Hundreds Of Dollars: Fighting Cancer, Costs
Hallelujah, Kim Green remembers thinking. Her life was about to get easier. For close to a decade, she had been making regular trips to the hospital, spending full days hooked up to machines that delivered chemotherapy to fight her breast cancer.
Targeting Leukemia Cell's Gene 'Addiction' Presents New Strategy For Treatment
An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells. The research, reported in EMBO Molecular Medicine, reveals how leukaemia cells become 'addicted' to genes, which if targeted could prevent diseased cells from developing.
Sequencing Of Patients' Genomes Offers New Hope
US researchers have decoded the entire genome of patients to identify the root cause of their diseases paving the way towards individual genomic treatments, according to newly published studies.
Drug Dramatically Reduces Nausea And Vomiting In Bone Marrow Transplant Patients
Bone marrow transplant patients say two of the most debilitating side effects of the treatment are nausea and vomiting caused by chemotherapy and radiation.
Findings From University Of Texas Broaden Understanding Of Epstein Barr Virus
Epstein-Barr virus (EBV) infection has been associated with Richter transformation in patients with chronic lymphocytic leukemia (CLL). A direct isothermal mRNA amplification method was developed for detection of EBV latent membrane protein 1 (LMP1) mRNA transcriptional activity in the peripheral blood of 135 chronic lymphocytic leukemia patients and 98 hematologically healthy control subjects, scientists in the United States report.
Gardening: It's Good For Your Health
Daily physical activity is a prerequisite for good health. Gardening is an excellent way to be physically active while growing healthy vegetables and fruits, as well as beautiful flowers. Active people are less likely than inactive people to be obese or have high blood pressure, type 2 diabetes, osteoporosis, coronary artery disease, stroke, depression, colon cancer and premature death.
Yale Study Details How And Why Of BPA's Dangers
Exposing a female fetus to a chemical found in plastics causes permanent changes in a daughter's uterus that might result in cancer -- and a research team led by a Yale doctor has figured out why.
Herbs Give Smaller Portion A Bigger Flavor
Want to build a healthier dinner plate? Add more vegetables and cut down on portion sizes of meat and starch, say health experts and nutritionists. The New American Plate section on the American Institute for Cancer Research Web site, www.aicr.org, says to aim for a meal made up of at least two-thirds vegetables, fruits, whole grains or beans and one-third or less animal protein.
Cheaper Treatments Have Pros And Cons
In the past, medical tourists -- those who travel overseas to have procedures done -- typically were wealthy. But with many consumers' budgets strapped and the rising cost of medical care, a growing number of Americans are traveling elsewhere to have operations and procedures in an attempt to save money.
Doctors, Patients Should Weigh Risks vs. Rewards Of Medical Imaging
After an imaging test revealed a small nodule in Dr. Len Lichtenfeld's lung, his doctor ordered a series of CT scans. But Lichtenfeld turned them down. As deputy chief medical officer of the American Cancer Society, Lichtenfeld knew the tiny nodule probably wasn't dangerous and that new research has documented an increased risk of cancer from CT scans' X-rays.
Board Recommends Continuation Of Mercks Phase IIB Study Of The Investigational Use Of Vorinostat In Relapsed Or Refractory Multiple Myeloma
Merck & Co., Inc. announced that an independent Data Safety and Monitoring Board recommended the continuation of VANTAGE 95, a Phase IIb clinical study of the investigational use of vorinostat in combination with bortezomib in patients with late-stage relapsed or refractory multiple myeloma who were refractory to bortezomib.
Warm Tomato Crisp Brightens A Winter Meal With Fresh Flavor And Plenty Of Lycopene
Bright red and juicy, cherry tomatoes are usually tossed into salads, eaten out of hand as a snack or used for a cheery garnish. But there's no reason you can't work the tiny tomatoes into a savory side dish.
Cells Of Aggressive Leukemia Hijack Normal Protein To Grow
Researchers have found that one particularly aggressive type of blood cancer, mixed lineage leukemia (MLL), has an unusual way to keep the molecular motors running. The cancer cells rely on the normal version of an associated protein to stay alive.
FDA Approves Rituxan Plus Chemotherapy For The Most Common Type Of Adult Leukemia
Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec announced the U.S. Food and Drug Administration (FDA) approved Rituxan (rituximab) in combination with fludarabine and cyclophosphamide (FC) for people with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia (CLL).
EntreMed Receives Orphan Drug Designation For ENMD-2076 In Leukemia
EntreMed, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company's lead oncology drug candidate, ENMD-2076, for the treatment of acute myeloid leukemia (AML).
NIH Grants Will Advance Novel Stem Cell Treatments For Blood Disorders
The new decade may herald an era of cell therapy -- treating human diseases by delivering highly specific beneficial cells. In the wake of an NIH decision late last year permitting federally funded researchers to use new lines of human embryonic stem cells, the door has opened more widely to stem cell research.
Poor And Inconsistent Reimbursement Of Oral Cancer Drugs Impairs Treatment
A comprehensive study of oral oncolytic (anti- cancer) drug treatments revealed that while their use is increasingly common, cancer patients frequently face barriers to accessing oral drugs compared to those delivered intravenously in oncology practice settings.
FDA Announces New Safety Plan For Agents Used To Treat Chemotherapy-Related Anemia
The U.S. Food and Drug Administration today approved a risk management program to inform healthcare providers and their patients about the risks of a class of drugs called Erythropoiesis-Stimulating Agents (ESAs). For patients with cancer, the program is also designed to help ensure the appropriate administration of these drugs, which they receive to treat anemia that can occur as a result of chemotherapy.
US Researchers Harness DNA Changes To Develop Cancer Test
US researchers unveiled a new way to fight cancer Thursday that uses the unique changes that occur in the DNA of cancerous cells to detect even the tiniest of cancers. Using cutting-edge DNA sequencing, researchers at Johns Hopkins University in Baltimore were able to identify radical genomic rearrangements that occur only in tumors, and not in healthy cells.







For more news about Non-Hodgkin Lymphoma go to MedWorm: Non-Hodgkin Lymphoma. This MedWorm page is more technical and is most likely more useful to oncologists. But for patients who want to know about cutting edge treatments and research for NHL, this MedWorm page will also be useful.

Powered by FirstRSS Plugin